Trials / Available
AvailableNCT06433128
Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections
Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections Who Have no Other Treatment Options
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Basilea Pharmaceutica · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- —
Summary
The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment options, primarily due to an infection with a resistant fungal pathogen, and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fosmanogepix solution for infusion | Fosmanogepix solution for infusion, 20 mg/mL for intravenous administration |
| DRUG | Fosmanogepix 400 mg tablets | Fosmanogepix 400 mg tablets for oral administration |
Timeline
- First posted
- 2024-05-29
- Last updated
- 2025-07-24
Source: ClinicalTrials.gov record NCT06433128. Inclusion in this directory is not an endorsement.